Amira’s lead Phase II-ready compound AM152 targets the lysophosphatidic acid 1 (LPA1) receptor. Bristol-Myers Squibb (BMS) is buying Amira Pharmaceuticals for $325 million up front and potentially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback